Dataset Information


Diagnostic and Clinical Impact of 18F-FDG PET/CT in Staging and Restaging Soft-Tissue Sarcomas of the Extremities and Trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center.

ABSTRACT: BACKGROUND:Soft-tissue sarcomas (STS) represent a wide heterogeneous class of rare tumors. The exact role 18F-fluorodeoxyglucose positron emission/computed tomography (18F-FDG PET/CT) in the evaluation of STS is not well established. The aim of the present study was to evaluate how the use of 18F-FDG PET/CT in STS could influence patient therapy planning, looking for a possible added value over computed tomography and magnetic resonance imaging-the most used modalities in the study of STS. Differences in SUVmax according to histologic subtype and tumor grade were also considered. METHODS:a total of 345 consecutive 18F-FDG PET/CT scans performed for initial staging (n = 171) or for suspected disease relapse (n = 174) in 282 patients with STS extracted from the local Information System database were retrospectively reviewed. RESULTS:18F-FDG PET/CT altered therapy planning in 80 cases (16.4% for staging and 29.9% in restaging), both for disease upstaging (58.8%) and downstaging (41.2%) Conclusions: 18F-FDG PET/CT could significantly influence management of patients with STS, particularly for restaging.

PROVIDER: S-EPMC7463806 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC7908760 | BioStudies
| S-EPMC8589741 | BioStudies
| S-EPMC5124833 | BioStudies
2013-01-01 | S-EPMC3762124 | BioStudies
| S-EPMC6910632 | BioStudies
| S-EPMC7025551 | BioStudies
| S-EPMC7599654 | BioStudies
| S-EPMC6651930 | BioStudies
| S-EPMC7584088 | BioStudies
| S-EPMC3915724 | BioStudies